Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label sleep laboratory study of piromelatine in idiopathic REM sleep behavior disorder
2023-506713-22-00Phase 2Completed
- Sponsor
- Neurim Pharmaceuticals
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Piromelatine in Isolated REM Sleep Behavior Disorder (iRBD), sponsored by Neurim Pharmaceuticals. Started Jan 2024; status: completed.
02
Drugs
Piromelatine
03
Conditions
Isolated REM Sleep Behavior Disorder (iRBD)
Beyond the preview
Go deeper on 2023-506713-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506713-22-00.